Document is current
Any future updates will be listed below
-
Authors
Duron, David I.
Tanguturi, Parthasaradhireddy
Campbell, Christopher S.
Chou, Kerry
Bejarano, Paul
Gabriel, Katherin A.
Bowden, Jessica L.
Mishra, Sanket
Brackett, Christopher
Barlow, Deborah
Houseknecht, Karen L.
Blagg, Brian S. J.
Streicher, John M. http://orcid.org/0000-0002-4173-7362
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA052340)
Arizona Biomedical Research Commission (ADHS18-198875)
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 21 June 2024
First Online: 26 June 2024
Competing interests
: JMS is an equity holder in <i>Teleport Pharmaceuticals, LLC</i> and <i>Botanical Results, LLC</i>, but these companies are not Hsp90-related. SM and BSJB are equity holders in <i>Grannus Therapeutic, Inc.</i> a company focused on the development of Hsp90 inhibitors; the company provided no support or involvement in this study. The authors have no other relevant conflicts of interest to declare.
